Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients

Vincenzo Catalano; Francesca Bergamo; Chiara Cremolini; Bruno Vincenzi; Francesca Negri; Paolo Giordani; Paolo Alessandroni; Rossana Intini; Silvia Stragliotto; Daniele Rossini; Beatrice Borelli; Daniele Santini; Donatella Sarti; Marco B L Rocchi; Sara Lonardi; Alfredo Falcone; Vittorina Zagonel; Rodolfo Mattioli; Francesco Graziano

doi:10.1007/s00432-019-03077-w

Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients

Vincenzo Catalano, Francesca Bergamo, Chiara Cremolini, Bruno Vincenzi, Francesca Negri, Paolo Giordani, Paolo Alessandroni, Rossana Intini, Silvia Stragliotto, Daniele Rossini, Beatrice Borelli, Daniele Santini, Donatella Sarti, Marco B L Rocchi, Sara Lonardi, Alfredo Falcone, Vittorina Zagonel, Rodolfo Mattioli, Francesco Graziano

Research output: Contribution to journal › Article › peer-review

Abstract

PURPOSE: In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis. We investigated whether bevacizumab combined with different chemotherapy regimens may have an impact on clinical outcomes of MCRC patients with mucinous histology.

METHODS: 685 MCRC patients were classified in mucinous adenocarcinoma (MC) and non-mucinous adenocarcinoma (NMC) and were treated with first-line bevacizumab plus fluoropyrimidine (FP)-based, oxaliplatin (OXA)-based, irinotecan (IRI)-based, or FOLFOXIRI.

RESULTS: Ninety-four (13.7%) patients had MC. With a median follow-up of 50 months, MC patients had a median overall survival (OS) of 28.2 months compared with 27.7 months for the NMC group [hazard ratio (HR) = 0.92; 95% confidence interval (CI) 0.70-1.19, P = 0.530]. The overall response rates for MC and NMC were 41.5% (95% CI 31.5-51.4) and 62.4% (95% CI 58.4-66.3), respectively (Chi-square test, P <0.003). After correcting for significant prognostic factors by multivariate Cox regression analysis, age, resection of the primary tumour, and number of metastatic sites were found to be associated with poorer OS, but not mucinous histology.

CONCLUSION: Compared with NMC, MCRC patients with mucinous histology treated with bevacizumab plus chemotherapy had comparable OS despite lower overall response rate.

Original language	English
Pages (from-to)	493-501
Number of pages	9
Journal	Journal of Cancer Research and Clinical Oncology
Volume	146
Issue number	2
Early online date	Nov 6 2019
DOIs	https://doi.org/10.1007/s00432-019-03077-w
Publication status	Published - Feb 2020

Keywords

Adenocarcinoma, Mucinous/drug therapy
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Bevacizumab/therapeutic use
Camptothecin/analogs & derivatives
Colorectal Neoplasms/drug therapy
Female
Fluorouracil/therapeutic use
Humans
Irinotecan/therapeutic use
Leucovorin/therapeutic use
Male
Middle Aged
Organoplatinum Compounds/therapeutic use
Oxaliplatin/therapeutic use
Prognosis
Retrospective Studies

Access to Document

10.1007/s00432-019-03077-w

Fingerprint Dive into the research topics of 'Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients'. Together they form a unique fingerprint.

Cite this

Catalano, V., Bergamo, F., Cremolini, C., Vincenzi, B., Negri, F., Giordani, P., Alessandroni, P., Intini, R., Stragliotto, S., Rossini, D., Borelli, B., Santini, D., Sarti, D., Rocchi, M. B. L., Lonardi, S., Falcone, A., Zagonel, V., Mattioli, R., & Graziano, F. (2020). Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. Journal of Cancer Research and Clinical Oncology, 146(2), 493-501. https://doi.org/10.1007/s00432-019-03077-w

Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology : a multicenter, retrospective analysis on 685 patients. / Catalano, Vincenzo; Bergamo, Francesca; Cremolini, Chiara; Vincenzi, Bruno; Negri, Francesca; Giordani, Paolo; Alessandroni, Paolo; Intini, Rossana; Stragliotto, Silvia; Rossini, Daniele; Borelli, Beatrice; Santini, Daniele; Sarti, Donatella; Rocchi, Marco B L; Lonardi, Sara; Falcone, Alfredo; Zagonel, Vittorina; Mattioli, Rodolfo; Graziano, Francesco.

In: Journal of Cancer Research and Clinical Oncology, Vol. 146, No. 2, 02.2020, p. 493-501.

Research output: Contribution to journal › Article › peer-review

Catalano, V, Bergamo, F, Cremolini, C, Vincenzi, B, Negri, F, Giordani, P, Alessandroni, P, Intini, R, Stragliotto, S, Rossini, D, Borelli, B, Santini, D, Sarti, D, Rocchi, MBL, Lonardi, S, Falcone, A, Zagonel, V, Mattioli, R & Graziano, F 2020, 'Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients', Journal of Cancer Research and Clinical Oncology, vol. 146, no. 2, pp. 493-501. https://doi.org/10.1007/s00432-019-03077-w

Catalano, Vincenzo ; Bergamo, Francesca ; Cremolini, Chiara ; Vincenzi, Bruno ; Negri, Francesca ; Giordani, Paolo ; Alessandroni, Paolo ; Intini, Rossana ; Stragliotto, Silvia ; Rossini, Daniele ; Borelli, Beatrice ; Santini, Daniele ; Sarti, Donatella ; Rocchi, Marco B L ; Lonardi, Sara ; Falcone, Alfredo ; Zagonel, Vittorina ; Mattioli, Rodolfo ; Graziano, Francesco. / Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology : a multicenter, retrospective analysis on 685 patients. In: Journal of Cancer Research and Clinical Oncology. 2020 ; Vol. 146, No. 2. pp. 493-501.

@article{fc013078dba04174a7a700dbc9b8e0a6,

title = "Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients",

abstract = "PURPOSE: In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis. We investigated whether bevacizumab combined with different chemotherapy regimens may have an impact on clinical outcomes of MCRC patients with mucinous histology.METHODS: 685 MCRC patients were classified in mucinous adenocarcinoma (MC) and non-mucinous adenocarcinoma (NMC) and were treated with first-line bevacizumab plus fluoropyrimidine (FP)-based, oxaliplatin (OXA)-based, irinotecan (IRI)-based, or FOLFOXIRI.RESULTS: Ninety-four (13.7%) patients had MC. With a median follow-up of 50 months, MC patients had a median overall survival (OS) of 28.2 months compared with 27.7 months for the NMC group [hazard ratio (HR) = 0.92; 95% confidence interval (CI) 0.70-1.19, P = 0.530]. The overall response rates for MC and NMC were 41.5% (95% CI 31.5-51.4) and 62.4% (95% CI 58.4-66.3), respectively (Chi-square test, P <0.003). After correcting for significant prognostic factors by multivariate Cox regression analysis, age, resection of the primary tumour, and number of metastatic sites were found to be associated with poorer OS, but not mucinous histology.CONCLUSION: Compared with NMC, MCRC patients with mucinous histology treated with bevacizumab plus chemotherapy had comparable OS despite lower overall response rate.",

keywords = "Adenocarcinoma, Mucinous/drug therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bevacizumab/therapeutic use, Camptothecin/analogs & derivatives, Colorectal Neoplasms/drug therapy, Female, Fluorouracil/therapeutic use, Humans, Irinotecan/therapeutic use, Leucovorin/therapeutic use, Male, Middle Aged, Organoplatinum Compounds/therapeutic use, Oxaliplatin/therapeutic use, Prognosis, Retrospective Studies",

author = "Vincenzo Catalano and Francesca Bergamo and Chiara Cremolini and Bruno Vincenzi and Francesca Negri and Paolo Giordani and Paolo Alessandroni and Rossana Intini and Silvia Stragliotto and Daniele Rossini and Beatrice Borelli and Daniele Santini and Donatella Sarti and Rocchi, {Marco B L} and Sara Lonardi and Alfredo Falcone and Vittorina Zagonel and Rodolfo Mattioli and Francesco Graziano",

year = "2020",

month = feb,

doi = "10.1007/s00432-019-03077-w",

language = "English",

volume = "146",

pages = "493--501",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology

T2 - a multicenter, retrospective analysis on 685 patients

AU - Catalano, Vincenzo

AU - Bergamo, Francesca

AU - Cremolini, Chiara

AU - Vincenzi, Bruno

AU - Negri, Francesca

AU - Giordani, Paolo

AU - Alessandroni, Paolo

AU - Intini, Rossana

AU - Stragliotto, Silvia

AU - Rossini, Daniele

AU - Borelli, Beatrice

AU - Santini, Daniele

AU - Sarti, Donatella

AU - Rocchi, Marco B L

AU - Lonardi, Sara

AU - Falcone, Alfredo

AU - Zagonel, Vittorina

AU - Mattioli, Rodolfo

AU - Graziano, Francesco

PY - 2020/2

Y1 - 2020/2

N2 - PURPOSE: In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis. We investigated whether bevacizumab combined with different chemotherapy regimens may have an impact on clinical outcomes of MCRC patients with mucinous histology.METHODS: 685 MCRC patients were classified in mucinous adenocarcinoma (MC) and non-mucinous adenocarcinoma (NMC) and were treated with first-line bevacizumab plus fluoropyrimidine (FP)-based, oxaliplatin (OXA)-based, irinotecan (IRI)-based, or FOLFOXIRI.RESULTS: Ninety-four (13.7%) patients had MC. With a median follow-up of 50 months, MC patients had a median overall survival (OS) of 28.2 months compared with 27.7 months for the NMC group [hazard ratio (HR) = 0.92; 95% confidence interval (CI) 0.70-1.19, P = 0.530]. The overall response rates for MC and NMC were 41.5% (95% CI 31.5-51.4) and 62.4% (95% CI 58.4-66.3), respectively (Chi-square test, P <0.003). After correcting for significant prognostic factors by multivariate Cox regression analysis, age, resection of the primary tumour, and number of metastatic sites were found to be associated with poorer OS, but not mucinous histology.CONCLUSION: Compared with NMC, MCRC patients with mucinous histology treated with bevacizumab plus chemotherapy had comparable OS despite lower overall response rate.

AB - PURPOSE: In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis. We investigated whether bevacizumab combined with different chemotherapy regimens may have an impact on clinical outcomes of MCRC patients with mucinous histology.METHODS: 685 MCRC patients were classified in mucinous adenocarcinoma (MC) and non-mucinous adenocarcinoma (NMC) and were treated with first-line bevacizumab plus fluoropyrimidine (FP)-based, oxaliplatin (OXA)-based, irinotecan (IRI)-based, or FOLFOXIRI.RESULTS: Ninety-four (13.7%) patients had MC. With a median follow-up of 50 months, MC patients had a median overall survival (OS) of 28.2 months compared with 27.7 months for the NMC group [hazard ratio (HR) = 0.92; 95% confidence interval (CI) 0.70-1.19, P = 0.530]. The overall response rates for MC and NMC were 41.5% (95% CI 31.5-51.4) and 62.4% (95% CI 58.4-66.3), respectively (Chi-square test, P <0.003). After correcting for significant prognostic factors by multivariate Cox regression analysis, age, resection of the primary tumour, and number of metastatic sites were found to be associated with poorer OS, but not mucinous histology.CONCLUSION: Compared with NMC, MCRC patients with mucinous histology treated with bevacizumab plus chemotherapy had comparable OS despite lower overall response rate.

KW - Adenocarcinoma, Mucinous/drug therapy

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Bevacizumab/therapeutic use

KW - Camptothecin/analogs & derivatives

KW - Colorectal Neoplasms/drug therapy

KW - Female

KW - Fluorouracil/therapeutic use

KW - Humans

KW - Irinotecan/therapeutic use

KW - Leucovorin/therapeutic use

KW - Male

KW - Middle Aged

KW - Organoplatinum Compounds/therapeutic use

KW - Oxaliplatin/therapeutic use

KW - Prognosis

KW - Retrospective Studies

U2 - 10.1007/s00432-019-03077-w

DO - 10.1007/s00432-019-03077-w

M3 - Article

C2 - 31691872

VL - 146

SP - 493

EP - 501

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 2

ER -